1887

Journal of Medical Microbiology logo

Volume 61, Issue 7

Fungal cell wall vaccines: an update Open Access

Abstract

This discussion is intended to be an overview of current advances in the development of fungal cell wall vaccines with an emphasis on ; it is not a comprehensive historical review of all fungal cell wall vaccines. Selected, more recent, innovative strategies for developing fungal vaccines will be highlighted. Both scientific and logistical obstacles related to the development of, and clinical use of, fungal vaccines will be discussed.

  • Published Online:
© 2012 SGM
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.041665-0
2012-07-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/61/7/895.html?itemId=/content/journal/jmm/10.1099/jmm.0.041665-0&mimeType=html&fmt=ahah

References

  1. Awasthi S. 2007; Dendritic cell-based vaccine against coccidioides infection. Ann N Y Acad Sci 1111:269–274 [View Article][PubMed]
     [Google Scholar]
  2. Bozza S., Gaziano R., Lipford G. B., Montagnoli C., Bacci A., Di Francesco P., Kurup V. P., Wagner H., Romani L. 2002; Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect 4:1281–1290 [View Article][PubMed]
     [Google Scholar]
  3. Bozza S., Perruccio K., Montagnoli C., Gaziano R., Bellocchio S., Burchielli E., Nkwanyuo G., Pitzurra L., Velardi A., Romani L. 2003; A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 102:3807–3814 [View Article][PubMed]
     [Google Scholar]
  4. Brandhorst T. T., Wüthrich M., Warner T., Klein B. 1999; Targeted gene disruption reveals an adhesin indispensable for pathogenicity of Blastomyces dermatitidis . J Exp Med 189:1207–1216 [View Article][PubMed]
     [Google Scholar]
  5. Brito L. A., Chan M., Baudner B., Gallorini S., Santos G., O’Hagan D. T., Singh M. 2011; An alternative renewable source of squalene for use in emulsion adjuvants. Vaccine 29:6262–6268 [View Article][PubMed]
     [Google Scholar]
  6. Capilla J., Clemons K. V., Liu M., Levine H. B., Stevens D. A. 2009; Saccharomyces cerevisiae as a vaccine against coccidioidomycosis. Vaccine 27:3662–3668 [View Article][PubMed]
     [Google Scholar]
  7. Cassone A. 2008; Fungal vaccines: real progress from real challenges. Lancet Infect Dis 8:114–124 [View Article][PubMed]
     [Google Scholar]
  8. Chow S. K., Casadevall A. 2011; Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis. Vaccine 29:1891–1898 [View Article][PubMed]
     [Google Scholar]
  9. Correia A., Lermann U., Teixeira L., Cerca F., Botelho S., da Costa R. M. G., Sampaio P., Gärtner F., Morschhäuser J. other authors 2010; Limited role of secreted aspartyl proteinases Sap1 to Sap6 in Candida albicans virulence and host immune response in murine hematogenously disseminated candidiasis. Infect Immun 78:4839–4849 [View Article][PubMed]
     [Google Scholar]
  10. Cutler J. E., Deepe G. S. Jr, Klein B. S. 2007; Advances in combating fungal diseases: vaccines on the threshold. Nat Rev Microbiol 5:13–28 [View Article][PubMed]
     [Google Scholar]
  11. Deepe G. S. Jr 1997; Prospects for the development of fungal vaccines. Clin Microbiol Rev 10:585–596[PubMed]
     [Google Scholar]
  12. Deepe G. S. Jr, Wüthrich M., Klein B. S. 2005; Progress in vaccination for histoplasmosis and blastomycosis: coping with cellular immunity. Med Mycol 43:381–389 [View Article][PubMed]
     [Google Scholar]
  13. Feldmesser M. 2005; Prospects of vaccines for invasive aspergillosis. Med Mycol 43:571–587 [View Article][PubMed]
     [Google Scholar]
  14. Feng Y., Guo S., Jiang T., Han X., Liu P., Wu T., Luo Y. 2011; Active immunization against Pneumocystis carinii with p55-v3 DNA vaccine in rats. Can J Microbiol 57:375–381 [View Article][PubMed]
     [Google Scholar]
  15. Fernandes V. C., Martins E. M., Boeloni J. N., Coitinho J. B., Serakides R., Goes A. M. 2011; Additive effect of rPb27 immunization and chemotherapy in experimental paracoccidioidomycosis. PLoS ONE 6:e17885 [View Article][PubMed]
     [Google Scholar]
  16. Fidel P. L. Jr, Cutler J. E. 2011; Prospects for development of a vaccine to prevent and control vaginal candidiasis. Curr Infect Dis Rep 13:102–107 [View Article][PubMed]
     [Google Scholar]
  17. Galgiani J. N., Peng T., Lewis M. L., Cloud G. A., Pappagianis D. The National Institute of Allergy and Infectious Diseases Mycoses Study Group 1996; Cerebrospinal fluid antibodies detected by ELISA against a 33-kDa antigen from spherules of Coccidioides immitis in patients with coccidioidal meningitis. J Infect Dis 173:499–502 [View Article][PubMed]
     [Google Scholar]
  18. Garcia J. P., Howard D. H. 1971; Characterization of antigens from the yeast phase of Histoplasma capsulatum . Infect Immun 4:116–125[PubMed]
     [Google Scholar]
  19. Gomez F. J., Gomez A. M., Deepe G. S. Jr 1991; Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells. Infect Immun 59:4459–4464[PubMed]
     [Google Scholar]
  20. Gomez F. J., Allendoerfer R., Deepe G. S. Jr 1995; Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis. Infect Immun 63:2587–2595[PubMed]
     [Google Scholar]
  21. Hennessey J. P. Jr, Schmidt C. S., Ibrahim A., Filler S., White C. J., Yeaman M., Fu Y., Edwards J. E. et al. 2011; A Phase 1 clinical evaluation of NDV3, a vaccine to prevent disease caused by Candida spp. and Staphylococcus aureus . In 51st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago. Washington, DC: American Society for Microbiology;
     [Google Scholar]
  22. Herbrecht R., Denning D. W., Patterson T. F., Bennett J. E., Greene R. E., Oestmann J. W., Kern W. V., Marr K. A., Ribaud P. other authors 2002; Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415 [View Article][PubMed]
     [Google Scholar]
  23. Hoyer L. L., Scherer S., Shatzman A. R., Livi G. P. 1995; Candida albicans ALS1: domains related to a Saccharomyces cerevisiae sexual agglutinin separated by a repeating motif. Mol Microbiol 15:39–54 [View Article][PubMed]
     [Google Scholar]
  24. Hsieh S. H., Lin J. S., Huang J. H., Wu S. Y., Chu C. L., Kung J. T., Wu-Hsieh B. A. 2011; Immunization with apoptotic phagocytes containing Histoplasma capsulatum activates functional CD8+ T cells to protect against histoplasmosis. Infect Immun 79:4493–4502 [View Article][PubMed]
     [Google Scholar]
  25. Hung C. Y., Gonzalez A., Wüthrich M., Klein B. S., Cole G. T. 2011; Vaccine immunity to coccidioidomycosis occurs by early activation of three signal pathways of T helper cell response (Th1, Th2, and Th17). Infect Immun 79:4511–4522 [View Article][PubMed]
     [Google Scholar]
  26. Ibrahim A. S., Spellberg B. J., Avenissian V., Fu Y., Filler S. G., Edwards J. E. Jr 2005; Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect Immun 73:999–1005 [View Article][PubMed]
     [Google Scholar]
  27. Ito J. I., Lyons J. M., Diaz-Arevalo D., Hong T. B., Kalkum M. 2009; Vaccine progress. Med Mycol 47:Suppl. 1S394–S400 [View Article][PubMed]
     [Google Scholar]
  28. Johnson S. M., Kerekes K. M., Lunetta J. M., Pappagianis D. 2007a; Characteristics of the protective subcellular coccidioidal T27K vaccine. Ann N Y Acad Sci 1111:275–289 [View Article][PubMed]
     [Google Scholar]
  29. Johnson S. M., Lerche N. W., Pappagianis D., Yee J. L., Galgiani J. N., Hector R. F. 2007b; Safety, antigenicity, and efficacy of a recombinant coccidioidomycosis vaccine in cynomolgus macaques (Macaca fascicularis). Ann N Y Acad Sci 1111:290–300 [View Article][PubMed]
     [Google Scholar]
  30. Kirkland T. N., Fierer J. 1985; Genetic control of resistance to Coccidioides immitis: a single gene that is expressed in spleen cells determines resistance. J Immunol 135:548–552[PubMed]
     [Google Scholar]
  31. Kirkland T. N., Raz E., Datta S. K. 2006; Molecular and cellular mechanisms of protective immunity to coccidioidomycosis. Vaccine 24:495–500 [View Article][PubMed]
     [Google Scholar]
  32. Klein B. S., Jones J. M. 1994; Purification and characterization of the major antigen WI-1 from Blastomyces dermatitidis yeasts and immunological comparison with A antigen. Infect Immun 62:3890–3900[PubMed]
     [Google Scholar]
  33. Lin L., Ibrahim A. S., Xu X., Farber J. M., Avanesian V., Baquir B., Fu Y., French S. W., Edwards J. E. Jr, Spellberg B. 2009; Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 5:e1000703 [View Article][PubMed]
     [Google Scholar]
  34. Liu M., Clemons K. V., Bigos M., Medovarska I., Brummer E., Stevens D. A. 2011a; Immune responses induced by heat killed Saccharomyces cerevisiae: a vaccine against fungal infection. Vaccine 29:1745–1753 [View Article][PubMed]
     [Google Scholar]
  35. Liu M., Capilla J., Johansen M. E., Alvarado D., Martinez M., Chen V., Clemons K. V., Stevens D. A. 2011b; Saccharomyces as a vaccine against systemic aspergillosis: ‘the friend of man’ a friend again?. J Med Microbiol 60:1423–1432 [View Article][PubMed]
     [Google Scholar]
  36. Lunetta J. M., Simmons K. A., Johnson S. M., Pappagianis D. 2007; Molecular cloning and expression of a cDNA encoding a Coccidioides posadasii 1,2-alpha-mannosidase identified in the coccidioidal T27K vaccine by immunoproteomic methods. Ann N Y Acad Sci 1111:164–180 [View Article][PubMed]
     [Google Scholar]
  37. Pappagianis D., Levine H. B. 1975; The present status of vaccination against coccidioidomycosis in man. Am J Epidemiol 102:30–41[PubMed]
     [Google Scholar]
  38. Pappagianis D. The Valley Fever Vaccine Study Group 1993; Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. Am Rev Respir Dis 148:656–660 [View Article][PubMed]
     [Google Scholar]
  39. Pappas P. G., Rex J. H., Lee J., Hamill R. J., Larsen R. A., Powderly W., Kauffman C. A., Hyslop N., Mangino J. E. other authors 2003; A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 37:634–643 [View Article][PubMed]
     [Google Scholar]
  40. Perruccio K., Bozza S., Montagnoli C., Bellocchio S., Aversa F., Martelli M., Bistoni F., Velardi A., Romani L. 2004; Prospects for dendritic cell vaccination against fungal infections in hematopoietic transplantation. Blood Cells Mol Dis 33:248–255 [View Article][PubMed]
     [Google Scholar]
  41. Phan Q. T., Myers C. L., Fu Y., Sheppard D. C., Yeaman M. R., Welch W. H., Ibrahim A. S., Edwards J. E. Jr, Filler S. G. 2007; Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol 5:e64 [View Article][PubMed]
     [Google Scholar]
  42. Pietrella D., Rachini A., Torosantucci A., Chiani P., Brown A. J., Bistoni F., Costantino P., Mosci P., d’Enfert C. other authors 2010; A β-glucan-conjugate vaccine and anti-β-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. Vaccine 28:1717–1725 [View Article][PubMed]
     [Google Scholar]
  43. Saville S. P., Lazzell A. L., Chaturvedi A. K., Monteagudo C., Lopez-Ribot J. L. 2008; Use of a genetically engineered strain to evaluate the pathogenic potential of yeast cell and filamentous forms during Candida albicans systemic infection in immunodeficient mice. Infect Immun 76:97–102 [View Article][PubMed]
     [Google Scholar]
  44. Scheckelhoff M., Deepe G. S. Jr 2002; The protective immune response to heat shock protein 60 of Histoplasma capsulatum is mediated by a subset of Vβ8.1/8.2+ T cells. J Immunol 169:5818–5826[PubMed] [CrossRef]
     [Google Scholar]
  45. Shao C., Qu J., He L., Zhang Y., Wang J., Zhou H., Wang Y., Liu X. 2005; Dendritic cells transduced with an adenovirus vector encoding interleukin-12 are a potent vaccine for invasive pulmonary aspergillosis. Genes Immun 6:103–114 [View Article][PubMed]
     [Google Scholar]
  46. Sheppard D. C., Yeaman M. R., Welch W. H., Phan Q. T., Fu Y., Ibrahim A. S., Filler S. G., Zhang M., Waring A. J., Edwards J. E. Jr 2004; Functional and structural diversity in the Als protein family of Candida albicans . J Biol Chem 279:30480–30489 [View Article][PubMed]
     [Google Scholar]
  47. Shubitz L. F., Dial S. M., Perrill R., Casement R., Galgiani J. N. 2008; Vaccine-induced cellular immune responses differ from innate responses in susceptible and resistant strains of mice infected with Coccidioides posadasii . Infect Immun 76:5553–5564 [View Article][PubMed]
     [Google Scholar]
  48. Spellberg B. 2011; Vaccines for invasive fungal infections. F1000 Med Rep 3:13 [View Article][PubMed]
     [Google Scholar]
  49. Spellberg B., Ibrahim A. S., Yeaman M. R., Lin L., Fu Y., Avanesian V., Bayer A. S., Filler S. G., Lipke P. other authors 2008; The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus . Infect Immun 76:4574–4580 [View Article][PubMed]
     [Google Scholar]
  50. Stevens D. A., Clemons K. V., Liu M. 2011; Developing a vaccine against aspergillosis. Med Mycol 49:Suppl. 1S170–S176 [View Article][PubMed]
     [Google Scholar]
  51. Tarcha E. J., Basrur V., Hung C. Y., Gardner M. J., Cole G. T. 2006; Multivalent recombinant protein vaccine against coccidioidomycosis. Infect Immun 74:5802–5813 [View Article][PubMed]
     [Google Scholar]
  52. Tewari R. P., Sharma D. K., Mathur A. 1978; Significance of thymus-derived lymphocytes in immunity elicited by immunization with ribosomes or live yeast cells of Histoplasma capsulatum . J Infect Dis 138:605–613 [View Article][PubMed]
     [Google Scholar]
  53. Torosantucci A., Bromuro C., Chiani P., De Bernardis F., Berti F., Galli C., Norelli F., Bellucci C., Polonelli L. other authors 2005; A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 202:597–606 [View Article][PubMed]
     [Google Scholar]
  54. Wüthrich M., Krajaejun T., Shearn-Bochsler V., Bass C., Filutowicz H. I., Legendre A. M., Klein B. S. 2011a; Safety, tolerability, and immunogenicity of a recombinant, genetically engineered, live-attenuated vaccine against canine blastomycosis. Clin Vaccine Immunol 18:783–789 [View Article][PubMed]
     [Google Scholar]
  55. Wüthrich M., Gern B., Hung C. Y., Ersland K., Rocco N., Pick-Jacobs J., Galles K., Filutowicz H., Warner T. other authors 2011b; Vaccine-induced protection against 3 systemic mycoses endemic to North America requires Th17 cells in mice. J Clin Invest 121:554–568 [View Article][PubMed]
     [Google Scholar]
  56. Wyckoff E. E., Pishko E. J., Kirkland T. N., Cole G. T. 1995; Cloning and expression of a gene encoding a T-cell reactive protein from Coccidioides immitis: homology to 4-hydroxyphenylpyruvate dioxygenase and the mammalian F antigen. Gene 161:107–111 [View Article][PubMed]
     [Google Scholar]
  57. Xin H., Cutler J. E. 2011; Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis. Clin Vaccine Immunol 18:1656–1667 [View Article][PubMed]
     [Google Scholar]
  58. Xin H., Dziadek S., Bundle D. R., Cutler J. E. 2008; Synthetic glycopeptide vaccines combining β-mannan and peptide epitopes induce protection against candidiasis. Proc Natl Acad Sci U S A 105:13526–13531 [View Article][PubMed]
     [Google Scholar]
  59. Xue J., Chen X., Selby D., Hung C. Y., Yu J. J., Cole G. T. 2009; A genetically engineered live attenuated vaccine of Coccidioides posadasii protects BALB/c mice against coccidioidomycosis. Infect Immun 77:3196–3208 [View Article][PubMed]
     [Google Scholar]
  60. Zelante T., De Luca A., Bonifazi P., Montagnoli C., Bozza S., Moretti S., Belladonna M. L., Vacca C., Conte C. other authors 2007; IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 37:2695–2706 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.041665-0
Loading
Fungal cell wall vaccines: an update
J. Med. Microbiol. 61, 895 (2012); https://doi.org/10.1099/jmm.0.041665-0
/content/journal/jmm/10.1099/jmm.0.041665-0
/content/journal/jmm/10.1099/jmm.0.041665-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error